Mechanism of action
The drug is a recombinant analogue of human GM-CSF. It acts on bone marrow progenitor cells, stimulating their proliferation and differentiation. Unlike G-CSF (e.g., filgrastim), molgramostim has a broader spectrum of activity, affecting the growth and functional activity of granulocytes, macrophages, and eosinophils.
Pharmacological effects
In addition to a quantitative increase in white blood cells, molgramostim provides functional activation of mature cells. The drug enhances phagocytosis, oxidative metabolism, and leukocyte cytotoxicity, which increases the body's ability to resist infectious agents and malignant cells.
Indications for use
The main objective of prescription is the treatment and prevention of leukopenia, as well as accelerating the recovery of myeloid hematopoiesis following courses of chemotherapy. The drug effectively reduces the risk of infectious complications associated with suppressed leukopoiesis.
Side effects and contraindications
The most commonly observed side effect is flu-like syndrome (fever, chills, myalgia, bone pain). Dyspnea, dyspeptic disorders (nausea, vomiting), asthenia, headache, and local injection site reactions may occur. Contraindications: leukemias (due to the risk of stimulating tumor cells) and lactation period.
Prescription details
The drug is available as a lyophilized powder in vials with dosages ranging from 50 to 700 mcg. Water for injections is used as a diluent. The dose is calculated individually: 10 mcg per 1 kg of the patient's body weight.
Briefly: answers to topical questions
What are the contraindications for the use of molgramostim?
Contraindications to the use of molgramostim include:
- Leukemias — due to the risk of stimulating malignant cells.
- Lactation period.
What are the pharmacokinetic features of molgramostim?
Molgramostim is administered parenterally — subcutaneously and intravenously. With subcutaneous administration, the peak concentration of the drug is reached in 3–4 hours.
Molgramostim — "Mol" (many) "gra" (granulocytes) "stim" (stimulating their growth path). GM-CSF = Granulocytes + Macrophages.
Class and exam questions
What is the fundamental difference between molgramostim and filgrastim?
Molgramostim is a GM-CSF and stimulates granulocytes, macrophages, and eosinophils. Filgrastim is a G-CSF that selectively stimulates the growth of neutrophilic granulocytes only.
Can molgramostim be used for iron deficiency anemia?
No, molgramostim is a stimulant of leukopoiesis, not erythropoiesis. Iron preparations are used to treat iron deficiency anemia.
Why is molgramostim contraindicated in leukemias?
The drug stimulates the proliferation of progenitor cells, which in leukemias can lead to the undesirable growth of malignant cells.
What else to study on this topic
- Comparative characteristics of G-CSF and GM-CSF.
- Differential diagnosis of immunostimulants (myelopid, amixin, CSF).
- Pharmacokinetic parameters following subcutaneous administration (Tmax).
- The role of colony-stimulating factors in chemotherapy protocols.
- Mechanisms of flu-like syndrome development during cytokine therapy.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Molgramostim" and another 5,304 pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.